ImmunoCellular Therapeutics, Ltd. (IMUC)
-NYSE MKT | Prev Close: | 2.19 |
|---|
| Open: | N/A |
|---|
| Bid: | 2.00 x 200 |
|---|
| Ask: | 2.45 x 1500 |
|---|
| 1y Target Est: | 10.00 |
|---|
| Beta: | 0.92 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 1.51 - 3.96 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 479,300 |
|---|
| Market Cap: | 115.47M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.26 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- [$$] Can Green Mountain Coffee and 4 Biotechs Climb?at Barrons.com(Mon, Jun 17)
- Immunotherapy: Four Companies on the Verge of Cancer-Treatment Breakthroughsat Minyanville(Mon, Jun 17)
- For Love And Money: 3 Growth Stocks From Casey's Alex Daleyat Seeking Alpha(Fri, Jun 14)
- SmithOnStocks Opines: June 9, 2013at Seeking Alpha(Sun, Jun 9)
- IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Fri, Jun 7)
- ImmunoCellular Therapeutics Announces Recommendation of Data Monitoring Committee to Continue ICT-107 Phase II Trial Following Interim AnalysisBusiness Wire(Fri, Jun 7)
- NeoStem's Subsidiary, PCT, Enters Into a Manufacturing Agreement With ImmunoCellular Therapeutics, Ltd. for Dendritic Cell Vaccines Targeting Brain and Other CancersGlobeNewswire(Mon, Jun 3)
- DelMar Pharmaceuticals To Present Updated Phase I GBM Data At ASCOat Seeking Alpha(Thu, May 30)
- ImmunoCellular Therapeutics to Present at Marcum MicroCap Conference on May 30thBusiness Wire(Wed, May 22)
- IMUC July Options Begin Tradingat TheStreet(Mon, May 20)
- IMMUNOCELLULAR THERAPEUTICS, LTD. FinancialsEDGAR Online Financials(Fri, May 17)
- ImmunoCellular Therapeutics Announces Issuance of Key Patent Covering ICT-107 Cancer Vaccine TargetBusiness Wire(Thu, May 16)
- IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatemEDGAR Online(Tue, May 14)
- 3 Biotech Stocks With Potentialat Seeking Alpha(Tue, May 14)
- ImmunoCellular Therapeutics: Marching Toward Top Line Data For ICT-107 In Q4 2013at Seeking Alpha(Fri, May 10)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.29 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.07 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, engages in developing and commercializing immune-based therapies for the treatment of brain, ovarian, and other solid tumors.
View More 
1.35%